Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vebreltinib + Platinum-based Doublet Chemotherapy in MET-Positive NSCLC
NCT06930794Phase 3Recruiting
- Sponsor
- Beijing Pearl Biotechnology Co., Ltd.
- Start
- Jul 2025
- Primary completion
- Feb 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vebreltinib in non-small cell lung cancer (NSCLC), sponsored by Beijing Pearl Biotechnology Co., Ltd.. Started Jul 2025; status: recruiting.
02
Drugs
vebreltinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06930794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06930794.